Chester County News and Community Website
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) last week added breast cancer treatment and genetic/familial high-risk assessment to its NCCN Guidelines Navigator™ platform, broadening access to digitized, …
NCCN Expands Digital Navigator With New Breast Cancer and Genetic Risk Resources Read More PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has announced new funding to support quality improvement projects aimed at advancing breast cancer outcomes. The …
NCCN Oncology Research Program Announces New Funding for Breast Cancer Quality Initiatives Read More PLYMOUTH MEETING, PA — A new study published in the September 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the effectiveness of a specialized tool for identifying …
Study Validates GO-PIMs Tool for Safer Cancer Care in Older Adults Read More PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate cancer. …
Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives Read More
WILMINGTON, DE — The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab significantly improves progression-free survival (PFS) for patients with HER2-positive metastatic …
ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast Cancer Read More WILMINGTON, DE — The Phase III MATTERHORN trial has delivered groundbreaking results, demonstrating that AstraZeneca’s IMFINZI® (durvalumab) combined with FLOT chemotherapy significantly improves outcomes for patients with resectable early-stage and …
MATTERHORN Trial Reveals Promising Results for Early Gastric Cancer Treatment Read More WILMINGTON, DE — Groundbreaking results from AstraZeneca’s Phase III SERENA-6 trial reveal a significant leap forward in the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The trial demonstrated …
AstraZeneca’s SERENA-6 Trial Marks Breakthrough in Breast Cancer Treatment Read More WILMINGTON, DE — AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its role as a backbone therapy across treatment stages for epidermal growth …
AstraZeneca Showcases TAGRISSO’s Potential in EGFR-Mutated Lung Cancer at ELCC 2025 Read More
WEST READING, PA — Tower Health is urging women to prioritize their breast health this March through its “Slam Dunk Mammo Screening” campaign. The initiative, running throughout the month, encourages women …
Tower Health Launches “Slam Dunk Mammo Screening” Campaign Read More
PHILADELPHIA, PA — A groundbreaking discovery from Dr. Filippo Veglia’s lab at The Wistar Institute has revealed how aggressive brain tumors reprogram immune cells, turning them from cancer-fighters into enablers …
Wistar Researchers Uncover Key Mechanism Behind Brain Tumor Immune Suppression Read More